1-17 of 17
Joyce O'Shaughnessy
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial

Rebecca A. Dent, Sung-Bae Kim, Mafalda Oliveira, Carlos Barrios, Joyce O’Shaughnessy, Steven J. Isakoff, Shigehira Saji, Ruffo Freitas-Junior, Manuel Philco, Igor Bondarenko, Qinshu Lian, Denise Bradley, Heather Hinton, Matthew J. Wongchenko, Sarah-Jayne Reilly, Nicholas Turner
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (19): 4329–4338.
https://doi.org/10.1158/1078-0432.CCR-24-0465
Published: 01 October 2024
View articletitled, Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial
Open the PDF for Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial in another window
Includes: Supplementary data
Journal Articles

Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups

Aditya Bardia, Javier Cortés, François-Clément Bidard, Patrick Neven, José Garcia-Sáenz, Phillipe Aftimos, Joyce O’Shaughnessy, Janice Lu, Giulia Tonini, Simona Scartoni, Alessandro Paoli, Monica Binaschi, Tomer Wasserman, Virginia Kaklamani
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (19): 4299–4309.
https://doi.org/10.1158/1078-0432.CCR-24-1073
Published: 01 October 2024
View articletitled, Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups
Open the PDF for Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups in another window
Includes: Supplementary data
Journal Articles

First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results

Peter Schmid, Nicholas C. Turner, Carlos H. Barrios, Steven J. Isakoff, Sung-Bae Kim, Marie-Paule Sablin, Shigehira Saji, Peter Savas, Gregory A. Vidal, Mafalda Oliveira, Joyce O'Shaughnessy, Antoine Italiano, Enrique Espinosa, Valentina Boni, Shane White, Beatriz Rojas, Ruffo Freitas-Junior, Yeesoo Chae, Igor Bondarenko, Jieun Lee, Cesar Torres Mattos, Jorge Luis Martinez Rodriguez, Lisa H. Lam, Surai Jones, Sarah-Jayne Reilly, Xiayu Huang, Kalpit Shah, Rebecca Dent
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (4): 767–778.
https://doi.org/10.1158/1078-0432.CCR-23-2084
Published: 16 February 2024
View articletitled, First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results
Open the PDF for First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results in another window
Includes: Supplementary data
Journal Articles

Intrinsic Subtype and Overall Survival of Patients with Advanced HR+/HER2− Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7

Aleix Prat, Nadia Solovieff, Fabrice André, Joyce O'Shaughnessy, David A. Cameron, Wolfgang Janni, Gabe S. Sonke, Yoon-Sim Yap, Denise A. Yardley, Ann H. Partridge, Astrid Thuerigen, Juan Pablo Zarate, Agnes Lteif, Fei Su, Lisa A. Carey
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (4): 793–802.
https://doi.org/10.1158/1078-0432.CCR-23-0561
Published: 16 February 2024
View articletitled, Intrinsic Subtype and Overall Survival of Patients with Advanced HR+/HER2− Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7
Open the PDF for Intrinsic Subtype and Overall Survival of Patients with Advanced HR+/HER2− Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7 in another window
Includes: Supplementary data
Journal Articles

Phase I Trial of a Novel Anti-HER2 Antibody–Drug Conjugate, ARX788, for the Treatment of HER2-Positive Metastatic Breast Cancer

Jian Zhang, Dongmei Ji, Weina Shen, Qin Xiao, Yajia Gu, Joyce O'Shaughnessy, Xichun Hu
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (19): 4212–4221.
https://doi.org/10.1158/1078-0432.CCR-22-0456
Published: 03 October 2022
View articletitled, Phase I Trial of a Novel Anti-HER2 Antibody–Drug Conjugate, ARX788, for the Treatment of HER2-Positive Metastatic Breast Cancer
Open the PDF for Phase I Trial of a Novel Anti-HER2 Antibody–Drug Conjugate, ARX788, for the Treatment of HER2-Positive Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study

Antoinette R. Tan, Gail S. Wright, Anu R. Thummala, Michael A. Danso, Lazar Popovic, Timothy J. Pluard, Hyo S. Han, Željko Vojnović, Nikola Vasev, Ling Ma, Donald A. Richards, Sharon T. Wilks, Dušan Milenković, Jie Xiao, Jessica Sorrentino, Janet Horton, Joyce O'Shaughnessy
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (4): 629–636.
https://doi.org/10.1158/1078-0432.CCR-21-2272
Published: 15 February 2022
View articletitled, Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study
Open the PDF for Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study in another window
Includes: Supplementary data
Journal Articles

Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs

Melody Cobleigh, Denise A. Yardley, Adam M. Brufsky, Hope S. Rugo, Sandra M. Swain, Peter A. Kaufman, Debu Tripathy, Sara A. Hurvitz, Joyce O'Shaughnessy, Ginny Mason, Vincent Antao, Haocheng Li, Laura Chu, Mohammad Jahanzeb
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (5): 1105–1113.
https://doi.org/10.1158/1078-0432.CCR-19-2350
Published: 02 March 2020
View articletitled, Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs
Open the PDF for Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs in another window
Includes: Supplementary data
Journal Articles

Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs

Sara A. Hurvitz, Joyce O'Shaughnessy, Ginny Mason, Denise A. Yardley, Mohammad Jahanzeb, Adam Brufsky, Hope S. Rugo, Sandra M. Swain, Peter A. Kaufman, Debu Tripathy, Laura Chu, Haocheng Li, Vincent Antao, Melody Cobleigh
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (8): 2433–2441.
https://doi.org/10.1158/1078-0432.CCR-18-2366
Published: 15 April 2019
View articletitled, Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs
Open the PDF for Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs in another window
Includes: Supplementary data
Journal Articles

Change in Topoisomerase 1–Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol

Hope S. Rugo, Javier Cortes, Ahmad Awada, Joyce O'Shaughnessy, Chris Twelves, Seock-Ah Im, Alison Hannah, Lin Lu, Sherwin Sy, Katie Caygill, Deborah A. Zajchowski, Darren W. Davis, Mary Tagliaferri, Ute Hoch, Edith A. Perez
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (14): 3348–3357.
https://doi.org/10.1158/1078-0432.CCR-17-3059
Published: 15 July 2018
View articletitled, Change in Topoisomerase 1–Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol
Open the PDF for Change in Topoisomerase 1–Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol in another window
Includes: Supplementary data
Journal Articles

MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer

Maura N. Dickler, Sara M. Tolaney, Hope S. Rugo, Javier Cortés, Véronique Diéras, Debra Patt, Hans Wildiers, Clifford A. Hudis, Joyce O'Shaughnessy, Esther Zamora, Denise A. Yardley, Martin Frenzel, Andrew Koustenis, José Baselga
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (17): 5218–5224.
https://doi.org/10.1158/1078-0432.CCR-17-0754
Published: 31 August 2017
View articletitled, MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer
Open the PDF for MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor–Positive Metastatic Breast Cancer

Weimin Li, Joyce O'Shaughnessy, Daniel Hayes, Mario Campone, Igor Bondarenko, Irina Zbarskaya, Etienne Brain, Marina Stenina, Olga Ivanova, Marie-Pascale Graas, Patrick Neven, Deborah Ricci, Thomas Griffin, Thian Kheoh, Margaret Yu, Michael Gormley, Jason Martin, Michael Schaffer, Kathy Zelinsky, Peter De Porre, Stephen R.D. Johnston
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (24): 6002–6009.
https://doi.org/10.1158/1078-0432.CCR-15-2452
Published: 15 December 2016
View articletitled, Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor–Positive Metastatic Breast Cancer
Open the PDF for Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor–Positive Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine

Joyce O'Shaughnessy, Hartmut Koeppen, Yuanyuan Xiao, Mark R. Lackner, Devchand Paul, Christopher Stokoe, John Pippen, Jr, Lea Krekow, Frankie Ann Holmes, Svetislava Vukelja, Deborah Lindquist, Scot Sedlacek, Ragene Rivera, Robert Brooks, Kristi McIntyre, Carrie Brownstein, Silke Hoersch, Joanne L. Blum, Stephen Jones
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (19): 4305–4311.
https://doi.org/10.1158/1078-0432.CCR-15-0636
Published: 30 September 2015
View articletitled, Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine
Open the PDF for Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine in another window
Includes: Supplementary data
Journal Articles

Poly (ADP-Ribose) Polymerase as a Novel Therapeutic Target in Cancer

Christina M. Annunziata, Joyce O'Shaughnessy
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (18): 4517–4526.
https://doi.org/10.1158/1078-0432.CCR-10-0526
Published: 14 September 2010
View articletitled, Poly (ADP-Ribose) Polymerase as a Novel Therapeutic Target in Cancer
Open the PDF for Poly (ADP-Ribose) Polymerase as a Novel Therapeutic Target in Cancer in another window
Journal Articles

Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer—A Plan to Move Forward

Gary J. Kelloff, Scott M. Lippman, Andrew J. Dannenberg, Caroline C. Sigman, Homer L. Pearce, Brian J. Reid, Eva Szabo, V. Craig Jordan, Margaret R. Spitz, Gordon B. Mills, Vali A. Papadimitrakopoulou, Reuben Lotan, Bharat B. Aggarwal, Robert S. Bresalier, Jeri Kim, Banu Arun, Karen H. Lu, Melanie E. Thomas, Helen E. Rhodes, Molly A. Brewer, Michele Follen, Dong M. Shin, Howard L. Parnes, Jill M. Siegfried, Alison A. Evans, William J. Blot, Wong-Ho Chow, Patricia L. Blount, Carlo C. Maley, Kenneth K. Wang, Stephen Lam, J. Jack Lee, Steven M. Dubinett, Paul F. Engstrom, Frank L. Meyskens, Jr., Joyce O'Shaughnessy, Ernest T. Hawk, Bernard Levin, William G. Nelson, Waun Ki Hong, for the AACR Task Force on Cancer Prevention
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (12): 3661–3697.
https://doi.org/10.1158/1078-0432.CCR-06-1104
Published: 15 June 2006
View articletitled, Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer—A Plan to Move Forward
Open the PDF for Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer—A Plan to Move Forward in another window
Journal Articles

The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development

Gary J. Kelloff, Kenneth A. Krohn, Steven M. Larson, Ralph Weissleder, David A. Mankoff, John M. Hoffman, Jeanne M. Link, Kathryn Z. Guyton, William C. Eckelman, Howard I. Scher, Joyce O'Shaughnessy, Bruce D. Cheson, Caroline C. Sigman, James L. Tatum, George Q. Mills, Daniel C. Sullivan, Janet Woodcock
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (22): 7967–7985.
https://doi.org/10.1158/1078-0432.CCR-05-1302
Published: 18 November 2005
View articletitled, The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development
Open the PDF for The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development in another window
Journal Articles

Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development

Gary J. Kelloff, John M. Hoffman, Bruce Johnson, Howard I. Scher, Barry A. Siegel, Edward Y. Cheng, Bruce D. Cheson, Joyce O'Shaughnessy, Kathryn Z. Guyton, David A. Mankoff, Lalitha Shankar, Steven M. Larson, Caroline C. Sigman, Richard L. Schilsky, Daniel C. Sullivan
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (8): 2785–2808.
https://doi.org/10.1158/1078-0432.CCR-04-2626
Published: 18 April 2005
View articletitled, Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
Open the PDF for Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development in another window
Journal Articles

Paclitaxel Chemotherapy after Autologous Stem-Cell Transplantation and Engraftment of Hematopoietic Cells Transduced with a Retrovirus Containing the Multidrug Resistance Complementary DNA (MDR1) in Metastatic Breast Cancer Patients

Kenneth H. Cowan, Jeffrey A. Moscow, Hui Huang, Jo Anne Zujewski, Joyce O’Shaughnessy, Brian Sorrentino, Kenneth Hines, Charles Carter, Erasmus Schneider, Georgie Cusack, Marianne Noone, Cynthia Dunbar, Seth Steinberg, Wyndham Wilson, Barrie Goldspiel, Elizabeth J. Read, Susan F. Leitman, Kevin McDonagh, Catherine Chow, Andrea Abati, Yu Chiang, Yawen N. Chang, Michael M. Gottesman, Ira Pastan, Arthur Nienhuis
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (7): 1619–1628.
Published: 01 July 1999
View articletitled, Paclitaxel Chemotherapy after Autologous Stem-Cell Transplantation and Engraftment of Hematopoietic Cells Transduced with a Retrovirus Containing the Multidrug Resistance Complementary DNA (MDR1) in Metastatic Breast Cancer Patients
Open the PDF for Paclitaxel Chemotherapy after Autologous Stem-Cell Transplantation and Engraftment of Hematopoietic Cells Transduced with a Retrovirus Containing the Multidrug Resistance Complementary DNA (MDR1) in Metastatic Breast Cancer Patients in another window